Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Taysha Gene Therapies, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 195
- +42 vs. Q3 2025
- Shares held
- 269.0M
- +8.09M (+3.1%) vs. Q3 2025
- Total value
- $1.48B
- +$625.8M (+73.3%) vs. Q3 2025
- New holders
- 64
- 62 more added
- Sold out
- 22
- 46 more reduced
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TSHA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 208 | $2.03B |
| Q1 2026 | 191 | $1.18B |
| Q4 2025 | 195 | $1.48B |
| Q3 2025 | 155 | $865.6M |
| Q2 2025 | 150 | $595.4M |
| Q1 2025 | 127 | $232.0M |
| Q4 2024 | 131 | $289.8M |
| Q3 2024 | 119 | $315.5M |
| Q2 2024 | 107 | $354.3M |
| Q1 2024 | 109 | $402.2M |
| Q4 2023 | 87 | $230.3M |
| Q3 2023 | 63 | $410.6M |
| Q2 2023 | 39 | $9.05M |
| Q1 2023 | 44 | $13.3M |
| Q4 2022 | 52 | $43.8M |
| Q3 2022 | 54 | $27.0M |
| Q2 2022 | 59 | $54.7M |
| Q1 2022 | 71 | $110.9M |
| Q4 2021 | 65 | $215.6M |
| Q3 2021 | 48 | $361.9M |
| Q2 2021 | 49 | $388.6M |
| Q1 2021 | 46 | $358.5M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Taysha Gene Therapies, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Marshall Wace, LLP | 0 | $0 | 0.00% | −476,865−100.0% | Sold out |
| Kovitz Investment Group Partners, LLC | 0 | $0 | 0.00% | −298,667−100.0% | Sold out |
| Readystate Asset Management LP | 0 | $0 | 0.00% | −161,972−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −53,483−100.0% | Sold out |
| Jain Global LLC | 0 | $0 | 0.00% | −52,608−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −48,123−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −47,328−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −46,643−100.0% | Sold out |
| Sender Co & Partners, Inc. | 0 | $0 | 0.00% | −27,121−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −16,389−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −16,094−100.0% | Sold out |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −12,200−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −10,367−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −4,289−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −1,280−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −690−100.0% | Sold out |
| Morton Brown Family Wealth, LLC | 0 | $0 | 0.00% | −260−100.0% | Sold out |
| Tybourne Capital Management (HK) Ltd | – | – | – | – | Not filed |
| CIBC Bancorp USA Inc. | – | – | – | – | Not filed |